Viemed Healthcare (NASDAQ:VMD) Rating Lowered to C+ at TheStreet

TheStreet downgraded shares of Viemed Healthcare (NASDAQ:VMD) from a b- rating to a c+ rating in a research note issued to investors on Monday morning, TheStreetRatingsTable reports.

Several other brokerages have also weighed in on VMD. Zacks Investment Research lowered Viemed Healthcare from a buy rating to a hold rating in a report on Thursday, August 26th. Acumen Capital restated a buy rating and set a C$14.00 target price on shares of Viemed Healthcare in a research report on Friday, September 17th. Finally, Bloom Burton upgraded Viemed Healthcare from an accumulate rating to a buy rating in a research report on Wednesday, August 4th. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Buy and an average target price of $11.50.

Shares of NASDAQ:VMD opened at $5.92 on Monday. Viemed Healthcare has a 1-year low of $5.77 and a 1-year high of $10.96. The firm has a market capitalization of $235.44 million, a PE ratio of 21.93 and a beta of 1.47. The business’s 50 day moving average is $6.28 and its 200-day moving average is $6.75. The company has a current ratio of 2.57, a quick ratio of 2.43 and a debt-to-equity ratio of 0.07.

Viemed Healthcare (NASDAQ:VMD) last announced its quarterly earnings data on Monday, August 2nd. The company reported $0.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. Viemed Healthcare had a return on equity of 13.63% and a net margin of 9.24%. The company had revenue of $27.40 million for the quarter, compared to analyst estimates of $27.50 million. On average, sell-side analysts predict that Viemed Healthcare will post 0.22 EPS for the current year.

Hedge funds have recently bought and sold shares of the company. Nisa Investment Advisors LLC bought a new stake in Viemed Healthcare during the second quarter worth about $56,000. BCM Advisors LLC bought a new stake in Viemed Healthcare during the second quarter worth about $70,000. Cambridge Investment Research Advisors Inc. bought a new stake in Viemed Healthcare in the second quarter valued at approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Viemed Healthcare by 135.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,259 shares of the company’s stock valued at $94,000 after buying an additional 5,319 shares during the period. Finally, Bard Associates Inc. bought a new stake in Viemed Healthcare in the second quarter valued at approximately $112,000. 56.43% of the stock is owned by institutional investors.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc engages in the provision of home healthcare solutions. Through its subsidiaries, it supplies home medical equipment which provides post-acute respiratory services. It also offers respiratory disease management and in-home sleep testing and sleep apnea treatment. The company was founded by Casey Hoyt, Max Hoyt, and Michael Moore on December 14, 2016 and is headquartered in Lafayette, LA.

Read More: How Buying a Call Option Works

Receive News & Ratings for Viemed Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viemed Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.